Palisade Bio (7NS0) AI Stock Analysis

Top Page

Palisade Bio

(Frankfurt:7NS0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageEssentially no debt reduces mandatory financial obligations and preserves flexibility for a clinical-stage company. The low-leverage structure gives management more capacity to allocate available capital toward research, regulatory planning, and potential partnering without substantial debt-service pressure.

Negative Factors

Pre-Revenue ModelThe absence of meaningful revenue leaves the company dependent on capital resources and future pipeline progress rather than recurring commercial cash inflows. Until a candidate reaches successful commercialization, financial performance is likely to remain highly sensitive to development outcomes and funding needs.

Palisade Bio (7NS0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 202.15M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -2.2
Beta (1Y): ―
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 14
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Palisade Bio Business Overview & Revenue Model

Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate...

Palisade Bio Risk Analysis

Palisade Bio disclosed 52 risk factors in its most recent earnings report. Palisade Bio reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Palisade Bio Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:7NS0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ELDN	46Neutral	$225.09M	-2.80	-136.45%	―	―	-1475.42%
OBIO	45Neutral	$355.22M	-5.97	-125.93%	―	986.14%	45.31%
PYXS	45Neutral	$216.45M	-1.28	-215.23%	―	291.42%	11.70%
CRBP	43Neutral	$81.62M	-0.65	-87.05%	―	―	-29.66%

* Healthcare Sector Average

Performance Comparison

DE:7NS0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:7NS0	Palisade Bio, Inc.	5.01	0.00	0.00%
CRBP	Corbus Pharmaceuticals Holdings	4.22	-8.08	-65.69%
ELDN	Eledon Pharmaceuticals, Inc.	2.77	-1.59	-36.47%
OBIO	Orchestra Biomed Holdings, Inc.	5.91	1.96	49.62%
PYXS	Pyxis Oncology, Inc.	1.81	-2.00	-52.49%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Palisade Bio AI Stock Analysis